# Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults

> **NCT05252845** · PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 127 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** R21/Matrix-M vaccination
- **DRUG:** DHA-PIP
- **DRUG:** PQ

## Key facts

- **NCT ID:** NCT05252845
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-04
- **Primary completion:** 2023-06-08
- **Final completion:** 2023-09-18
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252845, "Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05252845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*